glp-1 side effects pancreatitis Suspected drug-induced was rare but more common in patients taking agonists than sulfonylureas, a recent analysis of a VA database finds GLP-1 Agonists and Pancreatitis Risk:

Most importantly, they avoided the dangerous sugar crashes that came with older diabetes drugs like sulfonylureas

Glutathione for cosmetics represents a scientifically grounded antioxidant ingredient with strong consumer appeal

Stabilization first, peptides later if appropriate

That is why reading the fine print is so important

(Source: Novo Nordisk) In September 2024: Eli Lilly reported positive Phase 3 results for retatrutide, a novel triple GLP-1/GIP/glucagon receptor agonist, demonstrating an average weight loss of 24.2% at 48 weeks in adults with obesity, representing the highest weight loss achieved with any pharmacological agent to date and approaching bariatric surgery efficacy

In this review, we will examine the phenomenon of receptor dimerization with a focus on the role of the ghrelin receptor in such dimers and how this knowledge can aid in devising improved treatments for such disorders as Parkinsons disease, schizophrenia, obesity, depression, and diabetes